On the contrary, the advance on non-invasive techniques for molecular imaging of hormone receptors in BC, as illustrated by FES PET/CT, is more accurate for assessing ER-positive disease, detecting heterogeneity in tumors, and assessing therapy response. The gene discussed is NR4A1; the disease is breast cancer.